Noveko International Announces Exercise of Agents' Option for Additional
Gross Proceeds of $4 Million under its Private Placement

    
    /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
    DISSEMINATION IN THE UNITED STATES/

    Symbol: EKO / TSX
    

MONTREAL, Oct. 27 /CNW Telbec/ - Noveko International Inc. ("the Company") is pleased to announce that Desjardins Securities Inc., on its own behalf and on behalf of GMP Securities L.P., National Bank Financial Inc. and Paradigm Capital Inc. (collectively, the "Agents"), exercised the option granted to them by the Company ("the Agents' Option") pursuant to the agency agreement entered into on October 8, 2009 in connection with the previously announced best efforts private placement (the "Offering"). In a news release dated October 8, 2009, the Company had announced the closing of an initial amount of $11.7 million. The additional Units issued by the Company today upon due exercise of the Agents' Option generated additional gross proceeds of $4 million, for total gross proceeds of $15.7 million under the Offering.

Pursuant to this second Closing and as per the Offering's terms and conditions, each Unit was offered at $2.20 and consisted of one (1) Class A share of the Company (a "Class A Share") and one-half of one Class A Share purchase warrant (each whole Class A Share purchase warrant, a "Warrant"). Each Warrant entitles its holder to purchase, at a price of $3.00 per share, one Class A Share for a period of 36 months ending on October 8, 2012, subject to acceleration as described below. Accordingly, a total of 1,855,000 Class A shares were issued today by the Company and an additional 927,500 Class A shares may be issued upon due exercise of the Warrants.

The Warrants are subject to an acceleration clause whereby, if the Company's Class A Shares trade at a price per share equal to or higher than $4.50 on a weighted average basis for a period of 20 consecutive business days on the TSX, and upon notification by the Company through the issuance of a press release, the period during which the Warrants may be exercised will be decreased to a period of 30 days (the "New Exercise Period") that will begin at the last of the following dates: (i) the first business day immediately after completion of the 4 month plus one day hold period, or (ii) the first business day immediately after the above mentioned 20 consecutive business days, but, in both cases, the New Exercise Period shall not end later than the initial 36 month period. Upon the expiry of the New Exercise Period, the Warrants will no longer be exercisable.

The net proceeds of the Offering will be used to pursue the Company's global growth objectives, namely, fund the expansion of its international distribution networks, develop its current IP portfolio, develop new innovative applications, expand its production capacity, and for working capital purposes.

The Offering is being made pursuant to exemptions from prospectus requirements and is subject to the usual conditions and the receipt of all required regulatory approvals, including approval of the Toronto Stock Exchange.

The securities offered have not been registered, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This press release does not constitute an offer to sell or the solicitation of any offer to buy nor will there be any sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such province, state or jurisdiction.

Profile

Noveko International Inc. offers innovative solutions in the environmental and medical fields worldwide. Through its subsidiaries, the Company specializes primarily in the following business segments: the development, manufacturing and marketing of derivative products from its patented antimicrobial filtration technology, including air filters, surgical masks and respirators, along with other products with antimicrobial properties such as AZURO(TM) hand sanitizers - and the development, manufacturing and marketing of medical equipment, primarily portable real-time ultrasound scanners for use in human and veterinary medicine.

Certain statements set forth in this press release constitute forward-looking statements. In some cases, these statements are identified by the use of terms such as "may", "could", "might", "intend", "should", "expect", "project", "plan", "believe", "estimate" or other comparable variants. These statements are based on the information available at the time they are written, on assumptions made by management and on the expectations of management, acting in good faith, regarding future events, including those relating to economic conditions, fluctuations in exchange rates and operating expenses, and the absence of unusual events entailing supplementary expenditures. Although management considers these assumptions and expectations reasonable based on the information available at the time they are written, they could prove inaccurate. Forward-looking statements are also subject, by their very nature, to known and unknown risks and uncertainties such as those related to the industry, acquisitions, labor relations, credit, key officers, supply and product liability. The actual results of Noveko International Inc. could differ materially from those indicated or underlying these forward-looking statements. The reader is therefore recommended not to unduly rely on these forward-looking statements. Forward-looking statements do not reflect the potential impact of special items, any business combination or any other transaction that may be announced or occur subsequent to the date hereof. Unless otherwise required under securities laws, the Company does not intend and undertakes no obligation to update or revise the forward-looking statements to account for new information, new events or new circumstances.

SOURCE Noveko International Inc.

For further information: For further information: Chantal Vennat, Director, Investor Relations and Corporate Communications, Noveko International Inc., (514) 875-0606, http://www.noveko.com

Organization Profile

Noveko International Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890